Abstract: The present disclosure relates to a lithium secondary battery in which an abnormal voltage drop phenomenon is improved. The lithium secondary battery comprises a negative electrode comprising a negative electrode active material, a positive electrode comprising a positive electrode active material represented by Formula 1, a separator disposed between the positive electrode and the negative electrode, and a non-aqueous electrolyte solution, wherein the non-aqueous electrolyte solution comprises a lithium salt, a non-aqueous organic solvent, a compound represented by Formula 2 as a first additive, and lithium difluorophosphate as a second additive: LiaNixCOyM1zM2wO2??[Formula 1] wherein all the variables are described herein.

Abstract: The present disclosure provides a non-aqueous electrolyte including an additive for a non-aqueous electrolyte represented by Formula 1 below: wherein, R1 to R5 may each independently be any one selected from the group consisting of H, an alkenyl group having 2 to 20 carbon atoms, an alkynyl group having 2 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, a cycloalkyl group having 3 to 12 carbon atoms, a cycloalkenyl group having 3 to 12 carbon atoms, and a nitrile group.

Abstract: An aerosol generating device includes a first vaporizer configured to generate a first aerosol by heating a first liquid composition, a second vaporizer configured to generate a second aerosol by heating a second liquid composition, and a controller controlling power supplied to the first vaporizer and the second vaporizer, based on a first mode, in which a smokeless aerosol is generated, and a second mode, in which a transport amount of nicotine included in the second liquid composition is adjusted.

Abstract: The present application relates to creamer comprising vegetable lipids, casein, maltose, phosphates, and allulose.

Abstract: A composition for strengthening, developing, differentiating, or regenerating muscle, or preventing, ameliorating, or treating muscle loss or muscle fatigue includes a Schizonepeta tenuifolia extract as an effective component. The Schizonepeta tenuifolia extract as an effective component has the effects of restoring the viability of muscle cells, increasing the endurance time on the rotarod performance test, i.e., the holding time without falling off from the rod, compared to the control group, reducing the content of LDH, AST, and ALT in blood, increasing the grip strength, enhancing the expression amount of energy metabolism-related genes in muscle tissues, increasing the density of muscle fibers in muscle tissues, inducing a change in the fibroblast arrangement to have a well-organized structure, and reducing the expression of MuRF1 in muscle tissues, as compared to the control group.

Abstract: There is provided an apparatus for diagnosing whether or not an error has occurred in battery cells, the apparatus including a voltage measurement circuit for measuring a voltage of a battery cell, a data processing circuit for calculating a target statistical value indicating a state of the battery cell based on a voltage measured by the voltage measurement circuit, and calculates a cumulative statistical value, and a diagnosis circuit that determines whether or not an error has occurred in the battery cell through a cumulative determination operation of comparing the cumulative statistical value with a cumulative reference value, and counts a number of times of cumulative error when it is determined that the error has occurred in the battery cell in the cumulative determination operation.

Abstract: The present invention relates to a fusion protein comprising a SARS-CoV-2-derived receptor-binding domain and a nucleocapsid protein, and the use thereof. The fusion protein comprising a coronavirus-derived receptor-binding domain and a nucleocapsid protein is highly applicable to a multivalent vaccine composition having greatly improved in-vivo half-life and remarkably superior efficacy compared to an immunogenic composition comprising only a receptor-binding domain. In particular, the fusion protein can greatly improve the titer of the coronavirus-specific antibody formation and T-cell immune response, and is thus useful for the prevention and treatment of coronaviruses comprising SARS-CoV-2.

Abstract: A preparation process of 5-ethylidene-2-norbornene, including: introducing dicyclopentadiene into a dicyclopentadiene decomposition reactor to thermally decompose the dicyclopentadiene; introducing a product of the above step into a cyclopentadiene purification tower; introducing 1,3-butadiene, a solvent, and cyclopentadiene separated from the top of the cyclopentadiene purification tower into a Diels-Alder reactor to react the same; introducing a product of the immediate above step into a 1,3-butadiene removal tower to recover 1,3-butadiene from the top; introducing a mixture at the bottom of the 1,3-butadiene removal tower into a desolvation tower, and recycling a solvent and unreacted raw materials recovered from the top of the desolvation tower to the dicyclopentadiene decomposition reactor; introducing a mixture at the bottom of the desolvation tower into a 5-vinyl-2-norbornene separation tower to separate 5-vinyl-2-norbornene; and introducing the 5-vinyl-2-norbornene into an isomerization reactor to rea

Abstract: Provided are a fructose-4-epimerase variant having tagatose conversion activity, and a method of preparing tagatose using the same.

Abstract: The present disclosure relates to an information provision service system for an electric vehicle. More particularly, the present disclosure relates to an information provision service system for an electric vehicle using a vehicle sensor, wherein the system estimates a battery status and a distance to empty of an electric vehicle considering weather condition and to information based on a path, and estimates a battery status through an analysis of big data by using travel and weather information measured by a vehicle sensor and weather observation and forecast information from outside, thereby achieving accurate estimation.

Abstract: Provided are a composition for producing tagatose, comprising fructose-6-phosphate 4-epimerase, and a method of producing tagatose using the same.

Abstract: Provided are a tagatose-bisphosphate aldolase variant having tagatose conversion activity, and a method of preparing tagatose using the same.

Abstract: Provided are a novel fructose-C4-epimerase and a method of producing tagatose using the same.

Abstract: The present disclosure relates to a composition for tagatose production and a method for preparing tagatose using the same.

Abstract: The present application relates to a fructose-4-epimerase variant exhibiting tagatose conversion activity and a method for preparing tagatose using the same.

Abstract: The present disclosure relates to a composition for producing tagatose, comprising fructose-6-phosphate-4-epimerase, and a method of producing tagatose using the same.

Abstract: The present disclosure relates to novel fructose-C4-epimerase and a method of preparing tagatose using the same.

Abstract: Provided are a hexuronate C4-epimerase variant with improved activity in converting D-fructose by D-tagatose of hexuronate C4-epimerase and a method for production of D-tagatose using them.

Abstract: The present disclosure relates to novel D-psicose 3-epimerase and a method for producing psicose using the same.

Abstract: Provided are a fructose-4-epimerase variant having tagatose conversion activity, and a method of producing tagatose using the same.